Case Reports Open access

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

Authors

Published
24 July 2013
Section
Case Reports
DOI
10.4081/reumatismo.2013.134
Pages
134-137

Abstract

In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.

Keywords

Author Biography

  • A. Spadaro, Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.